▎WuXi AppTec Content Team Report

According to the JiKe PharmData database, as of September 26, since SeptemberAt least 7Chinese Companies Dedicated to Innovative Drug Development Announce Completion of New Round of Financing. These Rising Companies, Favored by the Capital Market, Are Committed to...Small molecules, siRNA drugs, recombinant protein drugs, base-edited NK cell therapies, iPSC-derived cell therapiesResearch and development, as well asMacromolecular drugs in the complement field, drug development targeting ion channelsetc.。

CGeneTech

Round:Series C Financing First Close

Financing Amount:Over 100 Million Yuan

On September 3, CGeneTech announced the completion of the first closing of its over CNY 100 million Series C financing round, with the investment from Tongren Boda. The funds raised will be used for itsClass 1 New Drug Product: SengliptinThe commercialization and subsequent clinical development of the innovative pipeline.CGeneTech is committed to the research and development of differentiated small molecule innovative drugs and has established a comprehensive coverage.Hypoglycemic, Anti-cancer, and Autoimmunewith a rich innovative pipeline, including a new generation of highly selectiveDPP-4 InhibitorsSengliptin is about to be approved for marketing.

CGeneTech also has multiple oncology pipelines entering the clinical stage, among whichNew Generation Small Molecule CXCR4 AntagonistCGT-1881 is under development for hematopoietic stem cell mobilization.FGFR/VEGFR Dual-Target InhibitorCGT-6321 is under development for the treatment of solid tumors,Next-Generation ALK InhibitorCGT-9475 is expected to address clinical pain points such as drug resistance and brain metastasis in lung cancer treatment. Among them, CGT-1881 and CGT-9475 have received clinical approval from the FDA.

Hygieia Bio

WheelRound: A2 Round

Financing Amount: Tens of Millions of Yuan

According to the press release from Hygieia, the companyHas authorized Fosun Pharma's subsidiary, Starry KunzeTreatment of Chronic Hepatitis B Virus InfectionsiRNADrug, has been approved by the NMPA and FDA for clinical use, demonstrating good safety, tolerability, and efficacy potential in Phase 1 clinical trials.The company's other two pipelines are also in Phase 1 studies, respectively forPipeline for the Treatment of Hyperlipoproteinemia (a)Kylo-11, andDual-targeting Liver THRβ Agonist PipelineKylo-0603。 

September 10,Junhe Alliance Biopharmaceutical (Tonghua) Co., Ltd. Announces CompletionOver 200 Million Yuan in B+ Round Financing,Led by SDIC Chuanghe, with participation from Hongsheng Capital, Yuanhe Holdings, So-Young Group, and Junhe Alliance Biopharmaceutical (Tonghua) Co., Ltd.The funds from this round of financing will be mainly used to advance the development of its research pipeline, accelerate the industrialization and commercial promotion of the product pipeline.Junhe Alliance Biopharmaceutical (Tonghua) Co., Ltd. focuses onRecombinant Protein Innovative Drugs and Synthetic Biology FieldInnovative product development, pipeline aroundSerious Medical, Consumer Medical, MetabolismIn the field of protein drugs, includingRecombinant Human Type I/III Collagen Solution and Formulations, Recombinant Botulinum Toxin Type Aetc.

On September 13, Crystal Egg Biotech announced the completionTens of millions of RMB in Series A financing. This round of financing was led by Qinzhi Capital, with existing shareholders Longmen Capital and Yueke Financial continuing to increase their investments.. Crystal Egg Biotechnology Company was founded in 2019 and is a company focused onInnovative Ion Channel Drug Development Company for Neuropsychiatric Disorders and Chronic Kidney DiseaseThe core team comes from internationally renowned research institutions and pharmaceutical companies such as Harvard University and Shanghai Institute of Materia Medica, and has invited Professor Erwin Neher, winner of the Nobel Prize in Physiology or Medicine and founder of the ion channel field, to serve as the chief scientific advisor.

According to the press release, Crystal Egg Biotech has established a unique ion channel target small molecule and protein drug technology platform—the IonFire platform (small molecule drugs) and the BigC platform (large molecule drugs), along with supporting platforms for the discovery of new ion channel targets, activity testing, protein structure analysis, and large molecule drug development.

On September 13, BaseBio announced the completionTens of millions of RMB in A2 round financing, led by the AEF GBA Venture Fund managed by Gobi Greater Bay Area (Gobi Partners GBA). This round of financing will be used to strengthen BaseBio's R&D team, optimize the product pipeline, and accelerate clinical trials, among other things.

Basel Biotech, founded in 2021, is committed to fundamental innovation in the field of gene editing, as well as the development of innovative cell therapies and gene editing products for the treatment of cancer and genetic diseases. In July this year, Basel Biotech's first product, NK510 –A Natural Killer Cell (NK) Product Based on Base Editing TechnologyHas submitted an IND application to China's NMPA and receivedAcceptanceIn addition to NK510, the product pipeline of Best Bio also includes multipleBase-edited NK cell products for hematologic malignancies and autoimmune diseases, as well as universal CAR immunotherapies and in vivo gene editing products。

On September 14, XingSaiRuiZhen announced the completion of an angel round of financing worth tens of millions of yuan and officially launched its angel+ round financing plan.This round of financing was jointly invested by Fosun Pharma's Fosun Jian Capital New Drug Innovation Fund and Chuangrui Investment Jiaxing Chuangyan Fund.The financing funds will be used forXingSaiRuiZhenThe continuous advancement of core pipelines and platforms, as well as the construction of the company's team and R&D laboratories.

XingSaiRuiZhen was founded in July 2022, incubated by Fosun Health Capital's New Drug Innovation Fund. The company is committed to continuously advancing regenerative medicine technology innovation and iPSC organ transplantation alternative product development, offering new treatment options for patients awaiting organ transplants.XingSaiRuiZhenAdvancing multiple key R&D projects, includingiPSC-Derived Corneal Endothelial Cell Product（CRG-101）, which is about to advance to the clinical application stage, andiPSC-Derived Islet Cell PipelineCRG-002The company has also built three iPSC regenerative medicine technology platforms, including CRG-iPSC (somatic cell reprogramming platform), CRG-EDIT (gene editing platform), and CRG-XDIF (stem cell multidirectional differentiation platform).

On September 24, Tianchen Bio announced the successful completionNearly 100 Million USD in B2 Round Financing, Led by Qiming Venture Partners with Additional Investment from Existing ShareholdersThrough this round of financing, Tianchen Bio will advance the clinical research of its core projects in China, expedite the product launch process, and facilitate international expansion. Tianchen Bio was established in 2020 and is a company dedicated to...Development of Macromolecular Innovative Drugs in the Field of Allergy and ComplementChinese Biotechnology Company.

In June this year, Tianchen Bio's leading projectNew Generation Anti-IgE Antibody DrugLP-003 Injection Initiated Phase 3 Clinical Trial for Treating Patients with Seasonal Allergic Rhinitis; the Product Features Low Dosage and Ultra-long Duration. LP-005, on the Other Hand, is a Potential "First-in-class" Drug.C5 and C3 Complement Bispecific Antibody,Phase 2 clinical trial for Paroxysmal Nocturnal Hemoglobinuria (PNH) has been initiated. According to the official website of CGeneTech, the company's preclinical pipeline also includesAAV-Mediated Complement InhibitorLP-008 Project: Development planned for the treatment of Age-related Macular Degeneration (AMD), etc.

[1] Official websites of various companies and publicly available information